Asymchem Group

We're off to Italy 🇮🇹 to explore the world of #peptides! Visit our experts at table #25. franck mevellec, Violeta Jordan, MBA, Mark Ashley . Our chemical macromolecule division (CMMD) supports traditional peptides, pseudopeptides, peptide+linker, peptide-drug conjugates, polymer-drug conjugates, and other highly active peptide molecules. Backed by a proven track record and extensive experience across 400+ projects, we accelerate your timelines and streamline your path to market. Learn More 🔗 https://okt.to/KiuJ7N Schedule a Meeting 🔗 https://okt.to/MOCg6X #peptides

Last week, we had the pleasure of celebrating Asymchem's launch ceremony, officially opening their new European headquarters right here at Discovery Park in Kent. 🎉 Asymchem Group, a global leader in pharma manufacturing, has chosen Kent as the ideal destination for its European HQ, thanks to our close proximity to London & Europe, the rich talent pool in the area, and the essential space we offer for growth. This new facility, housed in the former Pfizer small molecule site, will employ 70 team members, including many legacy Pfizer employees. We are excited about the additional hires planned as the pilot plant operations expand throughout the year. With a focus on innovative technologies for smarter, greener, and cost-effective pharma solutions, Asymchem is set to enhance its capabilities on-site, adding advanced equipment for peptide and oligonucleotide manufacture, as well as sustainability features for continuous flow and biocatalysis by 2025. Dr. Hao Hong, Chairman, Founder, and CEO of Asymchem, highlighted the significance of this milestone in meeting the growing demand for pharma services and supply. We share his enthusiasm for continuing a legacy of manufacturing excellence at Discovery Park. Welcome to Discovery Park, Asymchem! We're thrilled to have you here.🌟 #PharmaInnovation #DiscoveryPark #Kent #Asymchem

Last week, we had the pleasure of celebrating Asymchem's launch ceremony, officially opening their new European headquarters right here at Discovery Park in Kent. 🎉 Asymchem Group, a global leader in pharma manufacturing, has chosen Kent as the ideal destination for its European HQ, thanks to our close proximity to London & Europe, the rich talent pool in the area, and the essential space we offer for growth. This new facility, housed in the former Pfizer small molecule site, will employ 70 team members, including many legacy Pfizer employees. We are excited about the additional hires planned as the pilot plant operations expand throughout the year. With a focus on innovative technologies for smarter, greener, and cost-effective pharma solutions, Asymchem is set to enhance its capabilities on-site, adding advanced equipment for peptide and oligonucleotide manufacture, as well as sustainability features for continuous flow and biocatalysis by 2025. Dr. Hao Hong, Chairman, Founder, and CEO of Asymchem, highlighted the significance of this milestone in meeting the growing demand for pharma services and supply. We share his enthusiasm for continuing a legacy of manufacturing excellence at Discovery Park. Welcome to Discovery Park, Asymchem! We're thrilled to have you here.🌟 #PharmaInnovation #DiscoveryPark #Kent #Asymchem

ICYMI: We are pleased to announce the official opening of our new facility at Discovery Park in Sandwich, Kent, U.K., celebrated with a ribbon-cutting ceremony. This marks our dedication to delivering advanced small molecule solutions to the European market. For further details, refer to the press release. . 🔗https://okt.to/bDSZap . #smallmolecule #oligonucleotide #peptide #biocatalysis

The Asymchem team is headed to ACS Fall 2024 and will be at booth 2102! We're eager to connect with the chemistry community, share insights, and explore new possibilities. . Schedule a meeting with our team🔗 https://okt.to/jdHmFg . #ACSFall2024 #chemistry #pharma

On September 4th, Asymchem will be a proud Gold sponsor for the RNA Leaders USA Congress. The RNA Leaders program showcases comprehensive scientific tracks that delve into advanced development strategies, the latest trends, and innovative technologies within the expansive long and small RNA domains. Join us to explore these critical focus areas: ▶️ mRNA Vaccine & Therapeutics ▶️ Oligo-Based RNA Therapeutics ▶️ Next-Gen RNA ▶️ Delivery & Process Development ...and more categories listed in the full conference agenda. Be sure to also hear from our Vice President of Technical Business Development, Charles Chase discussing Fragment Based Ligation For Rapid Oligonucleotide Synthesis. . #RNA #oligonucleotide

We have officially inaugurated our new site at Discovery Park in Sandwich, Kent, U.K. with a ribbon cutting ceremony. This defines our commitment of bringing cutting-edge small molecule solutions to Europe. Read the press release for more details. . 🔗https://okt.to/0qALIV . #smallmolecule #oligonucleotide #peptide #biocatalysis

Since 2011, Asymchem has been a key supplier in the global carbapenem market, catering to both branded and generic segments. We also provide support for carbapenem APIs in late-stage clinical development, using our innovative continuous flow technology to improve safety and environmental impact. 🔗https://okt.to/uY9MHp

We're heading to 🇮🇹 for #peptides. Our chemical macromolecule division (CMMD) supports traditional peptides, pseudopeptides, peptide+linker, peptide-drug conjugates, polymer-drug conjugates, and other highly active peptide molecules. Backed by a proven track record and extensive experience across 400+ projects, we accelerate your timelines and streamline your path to market. Learn More 🔗 https://okt.to/TvBsS2 Schedule a Meeting 🔗 https://okt.to/a7GXR9

Join us tomorrow, July 30th at 10am ET! Our own, Charles Chase will be diving into a conversation titled, "Fragment-Based Oligonucleotide and Oligopeptide Synthesis." 🔗 to register: https://okt.to/lWzMQ5 . Advancements towards fragment-based approaches for oligonucleotide and oligopeptide synthesis will be presented. Leveraging Asymchem's expertise in synthetic chemistry, continuous processing, and enzyme engineering/biotransformation, we have developed an innovative liquid/solid phase hybrid synthesis platform using oligomer-fragments to manufacture complex oligonucleotides and peptides. Advantages, scope and limitations of fragment-based manufacturing methods, and the comparison to traditional solid-phase or liquid synthesis approaches, will be presented. . #oligonucleotide #peptides